Aerie wins FDA nod for second glaucoma drug

March 14, 2019

Aerie Pharmaceuticals (NSDQ:AERI) said this week that the FDA approved the company’s once-daily eye drop Rocklatan for the treatment of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.

The Durham, N.C.-based company’s product is a fixed-dose combination of latanoprost and netarsudil – the active ingredient in Aerie’s first drug, Rhopressa.

After winning an early FDA approval for Rhopressa in Dec. of 2017, Aerie launched the drug in the U.S. in April last year. The company reported that it’s slated to launch Rocklatan in the second quarter of this year.

Read More on Mass Device